B. Metzler Seel. Sohn & Co. Holding Ag Alnylam Pharmaceuticals, Inc. Call Options Transaction History
B. Metzler Seel. Sohn & Co. Holding Ag
- $10.1 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALNY
# of Institutions
655Shares Held
109MCall Options Held
2.13MPut Options Held
1.99M-
Capital World Investors Los Angeles, CA16.5MShares$4.44 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.4 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.57 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA6.21MShares$1.67 Billion0.28% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.41 Billion0.31% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33.1B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...